DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR Russian patent published in 2019 - IPC A61K31/4439 A61P35/00 

Abstract RU 2680246 C1

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used to treat cancer in a patient in need thereof. For this, a therapeutically effective amount of the alpha-isoform selective phosphatidylinositol 3-kinase inhibitor (I) is an orally administered to a patient in a daily dose of about 100 mg to about 450 mg for at least two five-consecutive day cycles, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days to about 3 days between one five-consecutive day cycle and its subsequent five- consecutive day cycle. Also provided is a method of treating cancer if said patient has a side effect after administration of said compound of formula (I).

EFFECT: group of inventions provides treatment of cancer in a patient.

12 cl, 15 dwg, 2 tbl, 1 ex

Similar patents RU2680246C1

Title Year Author Number
PI-3 KINASE DOSAGE REGIME 2013
  • Khiravat Samit
  • Massachezi Kristian
RU2630975C2
COMBINATION OF PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN TREATMENT OR PREVENTION OF HEAD AND NECK CANCER 2014
  • Khiravat Samit
  • Massachezi Kristian
  • Di Tomazo Emmanyuell
RU2672555C2
USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS 2011
  • Brakhmann, Zaskia Mariya
  • Fritch, Kristin
  • Mera, Saver-Mishel
  • Shnell, Kristian Rene
  • Garsiya-Echeverriya, Karlos
RU2589695C2
2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES 2012
  • Khuan Sichzhun
  • Kvadt Korneliya
  • Van Khoj-Tsin
  • Fritch Kristin
  • Shnell Kristian Rene
RU2624493C2
THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR 2017
  • Caponigro, Giordano
  • Meyer, Matthew John
  • Cooke, Vesselina
  • Stuart, Darrin
RU2774612C2
COMBINED THERAPY BY USING PENTAFLUOROBENZENE SULFONAMIDES 2000
  • Shuendner S'Juzan
  • Timmermanz Piter
  • Uoling Dzheki
RU2268054C2
METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY 2010
  • Armstrong Robert K.
  • Belli Barbara A.
RU2543348C2
COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT 2002
  • Bruns Kristian
  • Bukhdunger Ehlizabet
  • O`Rejlli Terens
  • Silberman Sandra Lita
  • Vartmann Markus
  • Vekkbekker Gizbert
RU2318517C2
PHARMACEUTICAL COMBINATIONS OF CDK4/6 INHIBITOR AND B-Raf INHIBITOR 2013
  • Kaponigro Dzhordano
  • Styuart Darrin
  • Kim Sunkiu
  • Loo Elis
  • Delech Skott
RU2685250C2
COMBINATIONS CONTAINING TRANSDUCTION SIGNAL INHIBITOR AND EPOTILONE DERIVATIVE 2002
  • Brandt Ral'F
  • Bukhdunger Ehlizabet
  • Khel'Din Karl-Khenrik
  • Estman Arne
  • Pitras Kristian
  • O`Rejli Terens
  • Rotermel Dzhon Dejvid
  • Traksler Peter
  • Vartmann Markus
RU2313345C2

RU 2 680 246 C1

Authors

Di Tomazo Emmanyuell

Zherma Mari-Karelin

Massachezi Kristian

Fritch Kristin

Shnell Kristian Rene

Tejvoret Randzhana

Dates

2019-02-19Published

2014-12-03Filed